Contents
On this page
- Influence of FDA risk-based monitoring guidance on the default monitoring approach
- Monitoring challenges specific to medical device trials
- Endpoint adjudication and the ISO 14155 standard
- Decentralized and remote monitoring as a partial response
- The research basis for treating the operator learning curve as a monitorable variable
- Site-level factors that complicate monitoring
Academy · Research Data, Analytics & AI · Medical Device Trial Monitoring
Common Challenges in Clinical Monitoring of Medical Device Trials
US Food and Drug Administration (FDA) guidance formally endorses risk-based monitoring, which concentrates oversight on the data most likely to affect participant safety and trial integrity rather than on verifying every data point at every site. Device trials, however, present monitoring challenges, such as operator learning curves and difficulty with blinding, that drug trials generally do not.
Clinical monitoring of a medical device trial is the continuous process of verifying that a study is conducted in accordance with its protocol, that the data collected are accurate and complete, and that the rights and safety of participants are protected; it is carried out primarily by clinical research associates who visit or remotely review investigational sites on behalf of the trial sponsor. Device trials present several challenges that are specific to devices rather than common to all clinical research: operators often require a learning period before they can use a new device competently, blinding both clinician and patient is frequently difficult or impossible for an implanted or procedurally delivered device, and device malfunctions can themselves become safety events requiring a separate reporting pathway. An understanding of these challenges, and of how current regulatory guidance addresses them, is important for anyone designing or overseeing the monitoring plan of a device trial.
Learning objectives
- How FDA's risk-based monitoring guidance changed what monitors are expected to verify, and why
- The specific challenges device trials add on top of standard clinical trial monitoring, including operator learning curves and blinding difficulty
- How an Endpoint Adjudication Committee and ISO 14155 fit into a device trial's monitoring structure
Common misconceptions
- “Rigorous clinical monitoring means a monitor verifying 100% of the data at every site visit.” FDA's final guidance on risk-based monitoring explicitly states that on-site monitoring visits at every site and 100% source data verification are not always necessary to ensure trial quality, and instead recommends that sponsors concentrate monitoring resources on the data and processes most likely to affect participant protection and overall trial integrity.
Influence of FDA risk-based monitoring guidance on the default monitoring approach
For many years, the default expectation in clinical research was that monitors should verify as much source data as possible at every site, an approach that is resource-intensive and does not necessarily direct attention to where it matters most. The guidance for industry issued by the U.S. Food and Drug Administration (FDA) on a risk-based approach to monitoring clinical investigations states directly that on-site monitoring at every site visit and 100% verification of all data are not always necessary, and recommends instead that sponsors develop a monitoring plan tailored to the specific risks of their study, informed by factors such as the complexity of the study design, the type of data collected and the risk to study participants1. This guidance explicitly supports greater use of centralized, remote and statistical monitoring techniques rather than reliance solely on in-person site visits, a shift that has become increasingly practical as electronic data capture systems have become standard in device trials1.
Monitoring challenges specific to medical device trials
Medical device trials present monitoring challenges that drug trials generally do not share. Many devices, particularly those requiring surgical implantation or procedural skill to deploy, are associated with an operator learning curve: a clinician's outcomes with a new device often improve over the first several cases as familiarity increases, which means that the monitor must track, and the sponsor must account for, operator experience as a variable that can affect outcome data independently of the actual performance of the device2. Blinding, a standard means of reducing bias in drug trials, is frequently difficult or impossible in device trials, since the clinician performing an implantation or procedure, and often the patient, can determine which device or approach was used; this shifts more of the burden of controlling bias onto other design features, such as blinded outcome assessment and pre-specified, objective endpoints2. Device malfunctions add a further monitoring dimension specific to this type of trial, since a malfunction can itself constitute a reportable adverse event requiring its own documentation and, depending on severity, a regulatory reporting pathway distinct from that of a typical drug-related adverse event3.
Endpoint adjudication and the ISO 14155 standard
Because blinding is often limited and operator variability is a genuine factor, device trials frequently rely on an Endpoint Adjudication Committee, a group of independent clinical experts who review trial events and determine, according to pre-specified, standardized criteria, whether a given event meets the definition of a study endpoint, without knowledge of the treatment arm or device received by the participant wherever this is feasible3. This mechanism is intended to add a degree of objectivity to endpoint determination that blinding alone cannot provide in many device studies. The international standard governing good clinical practice for device trials, ISO 14155, Clinical investigation of medical devices for human subjects, sets out requirements for trial design, conduct, monitoring, and reporting specifically adapted to devices, and sponsors and monitors working across multiple regulatory jurisdictions typically need to reconcile the requirements of this standard with FDA guidance and the FDA classification framework (Class I, II, and III devices, with Class III generally requiring the most rigorous premarket clinical evidence)4.
Decentralized and remote monitoring as a partial response
Several of the practical monitoring burdens described above (the scheduling of site visits, the volume of documentation and the difficulty of verifying continuous data streams from connected devices) have led sponsors towards decentralized and remote monitoring elements even in device trials, where feasible. FDA's 2023 final guidance on conducting clinical trials using decentralized elements explicitly addresses how remote data collection, the involvement of local healthcare providers and digital health technologies can be incorporated into the design and monitoring approach of a trial while still meeting applicable regulatory requirements for data quality and participant protection5. For device trials, decentralized elements are not a complete substitute for in-person monitoring where a device requires hands-on procedural training or implantation that can be properly verified only on site, but they can meaningfully reduce the monitoring burden for follow-up visits, the collection of patient-reported outcomes and routine safety checks that do not require physical examination of the device or procedure site; this is partly why industry risk-based monitoring frameworks, including that of TransCelerate, explicitly incorporate centralized and remote monitoring as core components rather than occasional substitutes6.
The research basis for treating the operator learning curve as a monitorable variable
The operator learning curve is not merely a theoretical concern; it is the subject of a dedicated methodological literature in surgical and procedural research. The IDEAL framework for evaluating surgical and other interventional procedures, developed by McCulloch and colleagues, explicitly identifies an early “exploration” and “development” stage in the lifecycle of a new procedure or device during which outcomes are expected to improve simply as operators gain experience, independently of any change in the device or technique itself, and recommends that evaluation studies account for this stage explicitly rather than pooling early and later outcomes as though they reflected a stable procedure6. Applied to device trial monitoring, this means that the monitor and biostatistician should, where feasible, record the case sequence number of each operator alongside outcome data, so that a learning-curve effect can be examined analytically rather than identified only informally or after the primary analysis of the trial has been completed. The broader regulatory pathway that a device follows, and the structure of its postmarket surveillance obligations once approved, both interact with the design of monitoring during the premarket trial itself; Van Norman's overview of FDA device approval pathways and Resnic and Normand's discussion of gaps in postmarket device surveillance both argue that premarket trial monitoring and postmarket surveillance should be planned as a continuum rather than as two unrelated regulatory phases78. International trials also need to reconcile FDA and ISO 14155 requirements with the applicable ICH E6(R3) good clinical practice guideline, which several regulators treat as the baseline standard for trial conduct and monitoring across both drug and device research9. The consequences of deficient premarket monitoring and postmarket surveillance are concrete: Zuckerman and colleagues' review of medical device recalls found that a substantial share of devices recalled for safety reasons serious enough to cause death or injury had reached the market through the less rigorous 510(k) pathway rather than the full Premarket Approval process, which underscores that the classification decision made early in the regulatory pathway of a device has downstream consequences for how much clinical monitoring and evidence generation the device receives before widespread use10.
Site-level factors that complicate monitoring
Beyond regulatory and design-level challenges, monitors in device trials routinely report practical, site-level obstacles: large volumes of device-specific technical and procedural documentation that must be checked alongside standard clinical records, limited physical space at sites for device storage and training materials, scheduling conflicts between monitoring visits and the limited periods during which the clinicians trained on the device are available, and inconsistent or fragmented record-keeping in which device-handling logs are kept separately from the main clinical record system. Open, specific communication between clinical research associates and site staff about what a given monitoring visit needs to verify, rather than a generic checklist provided with little context, is widely recommended as a means of reducing the friction created by these obstacles, together with escalation of unresolved site-level issues to sponsor management before they develop into protocol deviations.
Key points
Key points
Risk-based monitoring, endorsed in FDA guidance, concentrates oversight on the data most likely to affect participant safety and trial integrity rather than on verifying everything at every site. Device trials, however, add specific challenges (operator learning curves, limited blinding, malfunction reporting and the volume of site-level documentation) that a monitoring plan should address explicitly rather than inherit wholesale from drug-trial practice.
Practical application
Practical application
- The risk-based monitoring plan should be tailored to the specific risks of the device. The factors identified in FDA guidance (study complexity, data type and participant risk) should inform decisions on where centralized or remote monitoring is sufficient and where in-person source data verification is required.
- The operator learning curve should be addressed explicitly in the monitoring and analysis plan. Clinician experience with the device should be tracked and, where feasible, accounted for statistically as a variable, rather than early and later cases from the same operator being treated as equivalent.
- An Endpoint Adjudication Committee should be used where blinding is limited. Where clinicians or patients can reasonably infer which device or approach was used, independent, criteria-based event adjudication adds objectivity that blinding alone cannot provide in the design.
Frequently asked questions
No. The guidance states that on-site visits at every site and 100% source data verification are not always necessary, not that on-site visits are never needed; it recommends a tailored plan that may still include targeted on-site visits where the study's specific risks warrant them.
FDA classifies devices by risk level, with Class III generally covering higher-risk devices that require Premarket Approval and more rigorous clinical evidence, while many Class I and some Class II devices may qualify for a less demanding pathway; the classification affects how much clinical evidence a given trial is expected to generate and, therefore, the extent and type of monitoring it requires.
Blinding in a drug trial typically requires only that the tablet or infusion appear identical; blinding in a device trial often requires concealing a surgical approach, an implant or a procedural technique from the clinician performing it, which is frequently impractical or impossible, so device trials rely more heavily on blinded outcome assessment and adjudication instead.
ISO 14155 is an international standard specifically for the clinical investigation of medical devices, covering trial design, ethics, conduct and reporting; sponsors conducting trials across multiple countries typically need to satisfy both the relevant national regulatory guidance (such as that of the FDA in the US) and this international standard, which are related but not identical in their specific requirements.
References
- U.S. Food and Drug Administration. A Risk-Based Approach to Monitoring of Clinical Investigations: Questions and Answers, Guidance for Industry. 2013 (reissued 2019). read 10 October 2026. View FDA guidance document
- International Organization for Standardization. ISO 14155:2020 Clinical investigation of medical devices for human subjects — Good clinical practice. read 10 October 2026. View ISO 14155:2020
- U.S. Food and Drug Administration. Device Classification Panels and Premarket Approval Overview. read 10 October 2026. View FDA device classification resources
- U.S. Food and Drug Administration. Conducting Clinical Trials with Decentralized Elements, Guidance for Industry, Investigators, and Other Stakeholders. 2024. read 10 October 2026. View FDA decentralized clinical trials guidance
- TransCelerate BioPharma Inc. Risk-Based Monitoring Methodology. read 10 October 2026. View TransCelerate RBM resources
- McCulloch P, Altman DG, Campbell WB, et al; Balliol Collaboration. No surgical innovation without evaluation: the IDEAL recommendations. Lancet. 2009;374(9695):1105-1112. read 10 October 2026. View on The Lancet
- Van Norman GA. Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices. JACC Basic Transl Sci. 2016;1(4):277-287. read 10 October 2026. View on JACC: Basic to Translational Science
- Resnic FS, Normand SL. Postmarketing Surveillance of Medical Devices — Filling in the Gaps. N Engl J Med. 2012;366(10):875-877. read 10 October 2026. View on New England Journal of Medicine
- International Council for Harmonisation. ICH E6(R2) Guideline for Good Clinical Practice. read 10 October 2026. View ICH E6(R2) GCP guideline
- Zuckerman DM, Brown P, Nissen SE. Medical Device Recalls and the FDA Approval Process. Arch Intern Med. 2011;171(11):1006-1011. read 10 October 2026. View on Archives of Internal Medicine
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 10). Common Challenges in Clinical Monitoring of Medical Device Trials. Pubrica. https://pubrica.com/academy/systematic-review/common-challenges-for-successful-clinical-monitoring-of-medical-device/
Pubrica Academy. “Common Challenges in Clinical Monitoring of Medical Device Trials.” Pubrica, 10 Oct. 2026, pubrica.com/academy/systematic-review/common-challenges-for-successful-clinical-monitoring-of-medical-device/.
Pubrica Academy (2026) Common Challenges in Clinical Monitoring of Medical Device Trials. Pubrica. Available at: https://pubrica.com/academy/systematic-review/common-challenges-for-successful-clinical-monitoring-of-medical-device/ (Accessed: 15 October 2026).
Pubrica Academy. “Common Challenges in Clinical Monitoring of Medical Device Trials.” Pubrica. October 10, 2026. https://pubrica.com/academy/systematic-review/common-challenges-for-successful-clinical-monitoring-of-medical-device/
Pubrica Academy, ‘Common Challenges in Clinical Monitoring of Medical Device Trials’ (Pubrica, 10 October 2026) <https://pubrica.com/academy/systematic-review/common-challenges-for-successful-clinical-monitoring-of-medical-device/> accessed 15 October 2026.
Pubrica Academy. Common Challenges in Clinical Monitoring of Medical Device Trials. [Internet]. Pubrica; 2026 Oct 10 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/systematic-review/common-challenges-for-successful-clinical-monitoring-of-medical-device/
Pubrica Academy, “Common Challenges in Clinical Monitoring of Medical Device Trials,” Pubrica, Oct. 10, 2026. [Online]. Available: https://pubrica.com/academy/systematic-review/common-challenges-for-successful-clinical-monitoring-of-medical-device/
@misc{/la_clinical_monitoring_medical_device_trials_2026,
author = {{Pubrica Academy}},
title = {Common Challenges in Clinical Monitoring of Medical Device Trials},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/systematic-review/common-challenges-for-successful-clinical-monitoring-of-medical-device/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Device Trial Monitoring Plan Checklist
This checklist should be used when the monitoring plan of a device trial is being developed or reviewed.
[ ] Monitoring plan is tailored to study-specific risk factors, not a default 100%-verification approach [ ] Operator learning-curve tracking is built into data collection and analysis [ ] Blinding limitations are identified, and blinded outcome assessment or adjudication is used where blinding itself is not feasible [ ] Device malfunction reporting pathway is defined and distinct from standard adverse-event reporting [ ] Endpoint Adjudication Committee is in place where independent, criteria-based review adds needed objectivity [ ] Monitoring plan satisfies both relevant national guidance (e.g. FDA) and ISO 14155 where the trial spans jurisdictions
Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica's clinical research support team helps sponsors build risk-based, device-specific monitoring plans that satisfy FDA guidance and ISO 14155 while accounting for operator learning curves and blinding limitations.